렉세오 테라퓨틱스(LXEO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $4.15 (-0.72%), 시가총액 $0.40B, 52주 최저~최고 $2.70 ~ $10.63.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with
렉세오 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
렉세오 테라퓨틱스의 현재 주가는 $4.15 (-0.72%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
렉세오 테라퓨틱스의 시가총액은 약 $0.40B입니다.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AA